US equities
|
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Lexeo Therapeutics
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
May 07, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
April 22, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
April 16, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
March 13, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
March 11, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
March 11, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
February 05, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
LEXEO Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
December 18, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
December 11, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
Tickers
LXEO
Lexeo Therapeutics Announces Pricing of Initial Public Offering
November 02, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
August 28, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy
August 01, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
January 05, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
November 02, 2022
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics to Present Clinical and Preclinical Data at Upcoming Scientific Conferences
October 27, 2022
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission
October 18, 2022
From
LEXEO Therapeutics
Via
GlobeNewswire
LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
October 05, 2022
From
LEXEO Therapeutics
Via
GlobeNewswire
